Evaluation of Antioxidant and Antidiabetic Potential of Novel Derivatives of Aziridine

Diabetes mellitus is a significant metabolic disorder. The present research was based on the evaluation of antioxidant and antidiabetic potential of novel derivatives of aziridine. Albino rats (either sex) weighing 130–150g were provided by Animal House, Institute of Pharmaceutical Sciences and Research, Unnao. They were housed in healthy conditions, with a 12-hour light/dark cycle and a room temperature of 25°C. The acute toxicity (dose regimen) test of the synthesized aziridine derivatives was determined using Lorke’s method (1983). Diabetes was induced by a single intraperitoneal injection (a volume of 1ml/kg) of freshly prepared alloxan monohydrate solution (20mg/kg body weight). All the mice were divided into 5 groups (n=6) and treated for 21 days i.e., group 1 given normal saline; group 2 given alloxan (20mg/kg, p. o.); group 3 given alloxan (20mg/kg, p. o.) + glibenclamide (10mg/kg); group 4 given alloxan (20mg/kg, p. o.) + aziridine derivatives [A1] (50mg/kg, p. o.) and group 5 given alloxan (20mg/kg, p. o.) + synthesized aziridine derivatives [A4] (100mg/kg, p. o.). Antioxidant and anti-diabetic effects were evaluated using DPPH Scavenging capacity, total antioxidant, α-amylase and α-glucosidase inhibition, body weight and blood glucose level in OGTT. In results, in phase I and phase II, all the animals were found safe with no behavioural signs at all the dose levels. No mortality was seen in any animal. After 120 min, Alloxan (20mg/kg, p. o.) + aziridine derivative- A1 (50mg/kg, p. o.) and Alloxan (20mg/kg, p. o.) + aziridine derivative- A4 (50mg/kg, p. o.) treated mice showed blood glucose level as 137.12±0.38mg/dl and 134.36±0.29mg/dl, respectively. The inhibition rate was observed in dose-dependent manner. It concluded that aziridine derivatives A1 and A4 were demonstrated as significant antioxidant potential in DPPH scavenging assay and total antioxidant activity. When observed in animal study, A1 and A4 exhibited the hypoglycaemic action by lowering the blood glucose level and body weight of the mice. It suggests that aziridine derivatives (A1 and A4) are promising moieties which might be utilized in the management of oxidation and associated diabetes mellitus.